Sign in
Taking people in United StatesPhase 2

Tests immune-suppressing drugs for low blood counts in aplastic anemia or MDS

Tests horse anti-thymocyte globulin with other drugs in adults with aplastic anemia or MDS.

Key facts

Who runs it
M.D. Anderson Cancer Center
Where
Houston, United StatesSee the site
Trial code
Registry title
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
Status
Recruiting
Phase
Phase 2
People taking part
140 people, planned
Started
25 Jun 2012
Expected to end
30 Jun 2029
Type of study
Interventional
Treatments tested
  • Anti-Thymocyte Globulin
  • Cyclosporine
  • Filgrastim
  • Methylprednisolone
  • Pegfilgrastim
Record updated
22 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with aplastic anemia or low or intermediate-risk myelodysplastic syndrome (MDS) who need treatment for low blood counts.

Age
18 years and older
Sex
All sexes can join.
Disease stage
MDS that is Low or Int-1 risk by IPSS, or hypocellular. Or aplastic anemia in people who are not currently candidates for an allogeneic stem cell transplant. They need treatment for transfusion dependence, bleeding, severe fatigue or frequent infections.
Earlier treatment
Earlier treatment is allowed. People must have been off cytotoxic, immunosuppressive (except steroids) or targeted therapy for at least 2 weeks. They must have recovered from its side effects to grade 1 or less.

Main reasons for not taking part

  • Pregnant women
  • Known HIV infection
  • Uncontrolled illness, such as active infection, symptomatic heart failure, unstable angina, heart rhythm problems or a psychiatric illness that limits following the study
  • Documented allergy (hypersensitivity) to any of the study medicines

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Patients with the diagnosis of MDS (Low, Int-1 by IPSS, or hypocellular) who are either previously treated or untreated are eligible for this trial
  • Patients with the diagnosis of aplastic anemia who are either previously treated or untreated are eligible if they are not currently candidates for an allogeneic stem cell transplant
  • Patients ages 18 years and older are eligible
  • Patients must have been off of cytotoxic, immunosuppressive (except steroids), or targeted therapy for at least 2 weeks prior to entering this study, and have recovered from the toxic effects of that therapy to grade 1 or less
  • Adequate organ function as defined below:; liver function (bilirubin < 2mg/dL, AST <3 x ULN); kidney function (creatinine < 2.5 x ULN )
  • ECOG performance status of ≤ 2
  • Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
  • A negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial
  • Patient must have the ability to understand the requirements of the study and signed informed consent. A signed informed consent by the patient or his legally authorized representative is required prior to their enrollment on the protocol
  • Patients should have an indication for therapy for their disease such as transfusion dependence or morbidity associated with their cytopenia(s) such as bleeding, severe fatigue, or frequent/multiple infections (eg. neutropenia)

Who cannot take part

  • Known HIV infection
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Patient with documented hypersensitivity to any of the component medications
  • Pregnant women are excluded from this study. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the study agents, breastfeeding should be discontinued if the mother is treated on this study

Where in United States

  • M D Anderson Cancer CenterHouston, United StatesContact: Tapan M. KadiaTaking people

About the trial

What the trial wants to find out

This phase II trial studies methylprednisolone, horse anti-thymocyte globulin, cyclosporine, filgrastim, and/or pegfilgrastim or pegfilgrastim biosimilar in treating patients with aplastic anemia or low or intermediate-risk myelodysplastic syndrome. Horse anti-thymocyte globulin is made from horse blood and targets immune cells known as T-lymphocytes. Since T-lymphocytes are believed to be involved in causing low blood counts in aplastic anemia and in some cases of myelodysplastic syndromes, killing these cells may help treat the disease. Methylprednisolone and cyclosporine work to suppress immune cells called lymphocytes. This may help to improve low blood counts in aplastic anemia and myelodysplastic syndromes. Filgrastim and pegfilgrastim are designed to cause white blood cells to grow. This may help to fight infections and help improve the white blood cell count. Giving methylprednisolone and horse anti-thymocyte globulin together with cyclosporine, filgrastim, and/or pegfilgrastim may be an effective treatment for patients with aplastic anemia or myelodysplastic syndrome.

The group in the trial

  • Treatment (methylprednisolone, hATG, cyclosporine, G-CSF)Treatment being tested

    Patients receive methylprednisolone IV over 10 minutes on days 1-4 and IV or PO with taper over days 5-30. Patients also receive horse anti-thymocyte globulin IV over 8 hours daily on days 1-4, cyclosporine PO BID on days 1-180, and pegfilgrastim or pegfilgrastim biosimilar SC on day 5 and/or filgrastim SC beginning on day 5 and continuing until absolute neutrophil count recovers. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity.

    Treatment: Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, Methylprednisolone, and Pegfilgrastim

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase II Study of Horse Anti-Thymocyte Globulin (hATG), Cyclosporine, Methylprednisolone, and GCSF (Filgrastim or Pegfilgrastim) in Patients With Aplastic Anemia (AA), or Low/Int-1 Risk Myelodysplastic Syndrome (MDS)
Plain-language title
Tests immune-suppressing drugs for low blood counts in aplastic anemia or MDSGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
22 June 2026